List view / Grid view
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he…
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
Although Cordyceps mushrooms are challenging to cultivate, researchers have shown that they can be grown on edible insects to exploit their strong therapeutic potential.
Novel research has shown that morphological fingerprinting could help identify side effects of new bioactive compounds in drug discovery.
A recent pre-clinical study from Washington University School of Medicine showed that a new class of compounds can potentially improve multiple aspects of metabolic syndrome, including diabetes.
A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
In this Q&A, Professor Ross King from the University of Cambridge, UK, discusses how a new machine learning approach could aid drug discovery and development. The method learns from multiple problems and improves performance while it learns.
Researchers have found a quinoxaline-core containing, non-genotoxic lead compound that could treat schistosomiasis following optimisation.
Following Drug Target Review's webinar supported by Eurofins, speaker Dr Verena Albert answers the questions posed by the audience during the live event.
Following the latest Drug Target Review webinar, supported by Analytik Jena, we put the audience’s questions to the speakers to understand how hardware, software and labware challenges can be successfully overcome.
Using deep machine learning, researchers have completed the activity profiles, from chemistry to clinical level, for one million molecules.
Dr Sotirios Karathanasis discusses the history of cannabis as a treatment and delves into the process of turning plant-based medicines into clinically proven drugs.
Researchers have developed a technique to synthetically produce DNA oligonucleotides that avoids the degradation of phosphoramidites.
Scientists have developed PF74-like small molecules able to target the HIV-1 capsid protein, identifying four potent compounds.
